A Phase 3 interventional study of Imatinib mesylate in Leukemia, Myeloid, Chronic Phase, sponsored by Novartis Pharmaceuticals. Terminated at 75 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase — none open to participants now, none under way, none of them phase 3. imatinib · Leukemia, Myeloid, Chronic-Phase.
Among the 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2005, is one of 5 in phase 3, and was the 19th registered.
439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.
Browse Leukemia, Myeloid, Chronic-Phase studies →None of the 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase is open now. The open studies under Leukemia, Myeloid, Chronic-Phase, anywhere →
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 19 · Phase 3 5
First in 2000; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 476 is above the median of 43 across 322 interventional studies indexed under Leukemia, Myeloid, Chronic-Phase.
Median enrollment 56 across the 24 interventional studies. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis: 2 open now, 3 under way, none of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, this one is the only one that started in 2005, is one of 3 in phase 3, and was the 4th registered.
Novartis’s Leukemia, Myeloid, Chronic-Phase studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 14 in Leukemia, Myeloid, Chronic-Phase:
This tab as a report to print or save as PDF → With an account.
This study investigated the safety and efficacy of 400mg Versus 800mg imatinib in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate end organ function as defined by:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.
Drug: Imatinib mesylate
Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
Drug: Imatinib mesylate
Imatinib is packaged in bottles as 100mg and 400mg tablets
Also known as: STI571, Gleevec, Glivec
Percentage of Participants With Major Molecular Response (MMR) Rates at 12 Months
MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).
Time frame: 12 months
Percentage of Participants With Major Molecular Response (MMR) Rates at 24, 36, and 42 Months
MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).
Time frame: 24, 36 and 42 months
Percentage of Participants With Complete Cytogenetic Response (CCyR) Rate at 12, 24, 36, 42 Months
Cytogenetic response (CyR)is the percentage of Philadelphia chromosome positive metaphases (among at least 20 metaphase cells in bone marrow (BM)) with Complete Cytogenetic Response (CCyR) being 0 percent.
Time frame: 12, 24, 36, 42 months
Percentage of Participants With Complete Hematological Response (CHR) Rates at 12, 24, 36, and 42 Months
Complete Hematologic Response (CHR) is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement.
Time frame: 12, 24, 36, and 42 months
Percentage of Patients With Undetectable Levels of Bcr-Abl (A Fusion Gene of the Breakpoint Cluster Region [Bcr] Gene and Abelson Proto-oncogene [Abl] Genes) Transcripts
"Undetectable levels" or Complete molecular response is defined as Bcr-Abl ratio (%) on international scale (IS) \<= 0.0032% (≥ 4.5 log reduction of BCR-Abl transcripts from a standardized baseline).
Time frame: 12 , 24, 36 and 42 months
Time to First Major Molecular Response
MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally). Time to MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375. Time to first MMR was evaluated using the Kaplan-Meier method
Time frame: 42 months overall
Time to First Complete Cytogenetic Response
Cytogenetic response (CyR) is the percentage of Philadelphia positive metaphases (among at least 20 metaphase cells in Bone Marrow) with Complete Cytogenetic Response (CCyR) being 0 percent. Time to CCyR (months) = (date of first CCyR or censoring - date of randomization + 1) / 30.4375. Time to first CCyR was evaluated using the Kaplan-Meier method.
Time frame: 60 months overall
Time to First Complete Hematological Response (CHR)]
Complete Hematological Response (CHR) is defined is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement. Time to CHR (months) = (date of first CHR or censoring - date of randomization + 1) / 30.4375. Time to first CHR was evaluated using the Kaplan-Meier method.
Time frame: 60 months overall
Estimated Rate of Event Free Survival (EFS) in Two Treatment Arms
EFS on treatment was defined as time between randomization and either (1) death due to any cause during study treatment, (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment, (3) loss of complete hematological response (CHR), or (4) loss of major cytogenic response (MCyR) while on treatment. Estimated rate of EFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
Time frame: 60 months over all
Estimated Rate of Progression Free Survival (PFS) in Two Treatment Arms
PFS on study which was defined as time between randomization and either (1) death due to any cause on treatment of during follow-up after discontinuation of treatment or (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment during follow-up after discontinuation of study treatment. Estimated rate of PFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
Time frame: 60 months over all and follow up period
Estimated Rate of Progression to Accelerated Phase (AC)/Blast Crisis (BC) in Two Treatment Arms
(Accelerated Phase/Blast Crisis) AP/BC was defined as time between randomization and either (1) (Chronic Myeloid Leukemia) CML-related death (if death was primary reason for discontinuation) or (2) progression to AP or BC (during treatment). Estimated rate of AC/BC was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
Time frame: 60 months over all and follow up period
Estimated Rate of Overall Survival (OS) in Two Treatment Arms
OS was defined as time between randomization and death due to any cause during study treatment or during follow-up after discontinuation of treatment. Estimated rate of OS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
Time frame: 60 months over all and follow up period
Kaplan-Meier Estimates of Duration of First Major Molecular Response Until Confirmed Loss
Duration of MMR (months) = (date of first confirmed loss or censoring - date of MMR + 1 ) / 30.4375. Estimated rate of duration of first MMR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
Time frame: From First major molecular response to first confirmed loss or censoring
Kaplan-Meier Estimates of Duration of First Complete Cytogenetic Response (CCyR)
Duration of CCyR was defined as the time between date of CCyR and the earliest of either (1) loss of CCyR OR (2) (Chronic Myeloid Leukemia) CML-related death or progression to (Accelerated Phase/Blast Crisis) AP/BC during study treatment. Estimated rate of duration of first CCyR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
Time frame: From first complete cytogenetic response to first confirmed loss or censoring
Mean Actual Dose Intensity Per Day
The mean actual dose intensity per day from start of treatment up to last dose or discontinuation was evaluated up to Month 36. Actual dose intensity (mg/day) = total dose/time on treatment (periods of zero dose are included)
Time frame: start of treatment to Month 36
Imatinib Pharmacokinetic Trough Plasma Concentration (Cmin) at Month 12
Imatinib PK trough plasma concentration (Cmin) was defined as any pre-dose Imatinib plasma concentration
Time frame: Month 12
Estimated Rates of Progression Free Survival (PFS) on Treatment by Major Molecular Response (MMR)
A Landmark Kaplan-Meier analysis was performed for PFS at 42 months by MMR status at 6, 12, and 18 months to investigate their prognostic value.
Time frame: 42 months
Time to First Complete Molecular Response (CMR)]
Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene.
Time frame: 48 months overall
Number of Participants With the Effect of Imatinib on the Diabetic Participants With Known Concomitant Type II Diabetes
Time frame: 12 months
| Milestone | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| Started | 157 | 319 |
| Safety population | 157 | 316 |
| Completed | 14 | 35 |
| Not completed | 143 | 284 |
| Withdrew: Adverse event | 8 | 39 |
| Withdrew: Abnormal laboratory value | 2 | 2 |
| Withdrew: Abnormal procedure | 0 | 1 |
| Withdrew: Lack of efficacy | 20 | 41 |
| Withdrew: No longer requires study drug | 1 | 1 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 5 | 15 |
| Withdrew: Lost to follow-up | 2 | 7 |
| Withdrew: Administrative problem(study terminated) | 101 | 174 |
| Withdrew: Death | 1 | 3 |
MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).
| Percentage of participants | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| Percentage of Participants With Major Molecular Response (MMR) Rates at 12 Months | 38.9 | 45.1 |
MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).
| Percentage of participants | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 24 months | 53.5 | 50.8 |
| 36 months | 52.2 | 49.8 |
| 42 months | 51.6 | 50.2 |
Cytogenetic response (CyR)is the percentage of Philadelphia chromosome positive metaphases (among at least 20 metaphase cells in bone marrow (BM)) with Complete Cytogenetic Response (CCyR) being 0 percent.
| Percentage of Participants | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 12 months | 66.9 | 70.2 |
| 24 months | 76.4 | 76.8 |
| 36 months | 79.0 | 80.6 |
| 42 months | 80.3 | 81.5 |
Complete Hematologic Response (CHR) is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement.
| Percentage of participants | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 12 months | 94.9 | 93.7 |
| 24 months | 94.9 | 93.7 |
| 36 months | 96.2 | 94.4 |
| 42 months | 96.2 | 94.4 |
"Undetectable levels" or Complete molecular response is defined as Bcr-Abl ratio (%) on international scale (IS) \<= 0.0032% (≥ 4.5 log reduction of BCR-Abl transcripts from a standardized baseline).
| Percentage of Partcipants | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 12 Months | 4.5 | 4.7 |
| 24 Months | 11.5 | 10.3 |
| 36 Months | 12.7 | 13.2 |
| 42 Months | 14.6 | 12.5 |
MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally). Time to MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375. Time to first MMR was evaluated using the Kaplan-Meier method
| Months | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| Time to First Major Molecular Response | 13.6 (10.8 to 15.6) | 8.4 (8.3 to 9.0) |
Cytogenetic response (CyR) is the percentage of Philadelphia positive metaphases (among at least 20 metaphase cells in Bone Marrow) with Complete Cytogenetic Response (CCyR) being 0 percent. Time to CCyR (months) = (date of first CCyR or censoring - date of randomization + 1) / 30.4375. Time to first CCyR was evaluated using the Kaplan-Meier method.
| Months | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| Time to First Complete Cytogenetic Response | 10.8 (5.9 to 11.2) | 5.8 (5.8 to 6.0) |
Complete Hematological Response (CHR) is defined is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement. Time to CHR (months) = (date of first CHR or censoring - date of randomization + 1) / 30.4375. Time to first CHR was evaluated using the Kaplan-Meier method.
| Months | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| Time to First Complete Hematological Response (CHR)] | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
EFS on treatment was defined as time between randomization and either (1) death due to any cause during study treatment, (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment, (3) loss of complete hematological response (CHR), or (4) loss of major cytogenic response (MCyR) while on treatment. Estimated rate of EFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
| Percent probability | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 12 Months | 95.3 (90.5 to 97.7) | 98.0 (95.6 to 99.1) |
| 24 Months | 94.6 (89.5 to 97.3) | 95.3 (92.1 to 97.3) |
| 36 Months | 92.3 (86.5 to 95.7) | 94.5 (91.1 to 96.7) |
| 42 Months | 92.3 (86.5 to 95.7) | 94.1 (90.5 to 96.3) |
| 48 Months | 92.3 (86.5 to 95.7) | 93.6 (89.9 to 96.0) |
| 60 Months | 90.3 (82.7 to 94.7) | 93.6 (89.9 to 96.0) |
PFS on study which was defined as time between randomization and either (1) death due to any cause on treatment of during follow-up after discontinuation of treatment or (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment during follow-up after discontinuation of study treatment. Estimated rate of PFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
| Percent probability | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 12 Months | 97.4 (93.2 to 99.0) | 98.7 (96.5 to 99.5) |
| 24 Months | 95.9 (91.2 to 98.2) | 97.5 (94.9 to 98.8) |
| 36 Months | 94.4 (89.0 to 97.1) | 96.7 (93.7 to 98.3) |
| 42 Months | 94.4 (89.0 to 97.1) | 96.3 (93.2 to 98.0) |
| 48 Months | 94.4 (89.0 to 97.1) | 95.8 (92.5 to 97.7) |
| 60 Months | 94.4 (89.0 to 97.1) | 95.8 (92.5 to 97.7) |
(Accelerated Phase/Blast Crisis) AP/BC was defined as time between randomization and either (1) (Chronic Myeloid Leukemia) CML-related death (if death was primary reason for discontinuation) or (2) progression to AP or BC (during treatment). Estimated rate of AC/BC was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
| Percent probability | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 12 Months | 97.4 (93.2 to 99.0) | 99.0 (97.0 to 99.7) |
| 24 Months | 95.9 (91.2 to 98.2) | 97.9 (95.3 to 99.0) |
| 36 Months | 95.2 (90.1 to 97.7) | 97.5 (94.7 to 98.8) |
| 42 Months | 95.2 (90.1 to 97.7) | 97.0 (94.1 to 98.5) |
| 48 Months | 95.2 (90.1 to 97.7) | 97.0 (94.1 to 98.5) |
| 60 Months | 95.2 (90.1 to 97.7) | 97.0 (94.1 to 98.5) |
OS was defined as time between randomization and death due to any cause during study treatment or during follow-up after discontinuation of treatment. Estimated rate of OS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
| Percent probability | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 12 Months | 98.7 (94.9 to 99.7) | 99.0 (97.1 to 99.7) |
| 24 Months | 97.4 (93.2 to 99.0) | 97.8 (95.4 to 98.9) |
| 36 Months | 96.1 (91.4 to 98.2) | 95.5 (92.5 to 97.3) |
| 42 Months | 94.7 (89.7 to 97.2) | 94.8 (91.6 to 96.8) |
| 48 Months | 94.0 (88.7 to 96.8) | 93.4 (89.7 to 95.8) |
| 60 Months | 94.0 (88.7 to 96.8) | 93.4 (89.7 to 95.8) |
Duration of MMR (months) = (date of first confirmed loss or censoring - date of MMR + 1 ) / 30.4375. Estimated rate of duration of first MMR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
| Percent probability | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 3 Months | 100 (100 to 100) | 96.3 (92.9 to 98.0) |
| 6 Months | 98.3 (93.3 to 99.6) | 90.7 (86.2 to 93.8) |
| 9 Months | 97.4 (92.2 to 99.2) | 90.2 (85.7 to 93.4) |
| 12 Months | 95.6 (89.8 to 98.2) | 88.4 (83.6 to 91.9) |
| 15 Months | 93.8 (87.4 to 97.0) | 87.5 (82.5 to 91.2) |
| 18 Months | 92.8 (86.2 to 96.4) | 86.1 (80.9 to 90.0) |
| 21 Months | 90.9 (83.8 to 95.0) | 85.1 (79.8 to 89.1) |
| 24 Months | 89.9 (82.5 to 94.3) | 83.6 (78.0 to 87.8) |
| 30 Months | 88.5 (80.5 to 93.4) | 82.5 (76.8 to 86.9) |
| 36 Months | 85.1 (75.6 to 91.1) | 81.1 (75.1 to 85.8) |
| 42 Months | 85.1 (75.6 to 91.1) | 77.9 (70.4 to 83.8) |
Duration of CCyR was defined as the time between date of CCyR and the earliest of either (1) loss of CCyR OR (2) (Chronic Myeloid Leukemia) CML-related death or progression to (Accelerated Phase/Blast Crisis) AP/BC during study treatment. Estimated rate of duration of first CCyR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).
| Percent probability | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| 6 Months | 99.1 (94.0 to 99.9) | 99.2 (96.7 to 99.8) |
| 12 Months | 98.2 (93.1 to 99.6) | 97.8 (94.7 to 99.1) |
| 18 Months | 98.2 (93.1 to 99.6) | 97.3 (94.1 to 98.8) |
| 24 Months | 98.2 (93.1 to 99.6) | 96.8 (93.3 to 98.4) |
| 30 Months | 98.2 (93.1 to 99.6) | 96.8 (93.3 to 98.4) |
| 36 Months | 98.2 (93.1 to 99.6) | 95.9 (91.9 to 98.0) |
| 42 Months | 98.2 (93.1 to 99.6) | 95.9 (91.9 to 98.0) |
The mean actual dose intensity per day from start of treatment up to last dose or discontinuation was evaluated up to Month 36. Actual dose intensity (mg/day) = total dose/time on treatment (periods of zero dose are included)
| mg/day | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| Mean Actual Dose Intensity Per Day | 399.3 ± 83.84 | 643.3 ± 158.63 |
Imatinib PK trough plasma concentration (Cmin) was defined as any pre-dose Imatinib plasma concentration
| mg/mL | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| Imatinib Pharmacokinetic Trough Plasma Concentration (Cmin) at Month 12 | 1458.2 ± 2259.5 | 739.58 ± 1321.09 |
A Landmark Kaplan-Meier analysis was performed for PFS at 42 months by MMR status at 6, 12, and 18 months to investigate their prognostic value.
| Percent probability | Imatinib 400 mg | Imatinib 800 mg |
|---|---|---|
| No MMR at 6 Months | 94.8 (88.0 to 97.8) | 95.6 (90.3 to 98.0) |
| MMR at 6 Months | 100 (100 to 100) | 99.0 (93.2 to 99.9) |
| No MMR at 12 Months | 93.2 (82.9 to 97.4) | 94.6 (87.4 to 97.7) |
| MMR at 12 Months | 100 (100 to 100) | 99.3 (95.0 to 99.9) |
| No MMR at 18 Months | 96.7 (78.6 to 99.5) | 97.0 (88.6 to 99.3) |
| MMR at 18 Months | 98.7 (91.2 to 99.8) | 99.3 (95.2 to 99.9) |
Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib 400mg | — | 42/157 (26.8%) | 157/157 (100%) |
| Imatinib 800mg | — | 121/316 (38.3%) | 315/316 (99.7%) |
| Event | Imatinib 400mg | Imatinib 800mg |
|---|---|---|
| PyrexiaGeneral disorders | 3/157 | 13/316 |
| NeutropeniaBlood and lymphatic system disorders | 5/157 | 12/316 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/157 | 9/316 |
| AnaemiaBlood and lymphatic system disorders | 3/157 | 6/316 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/157 | 5/316 |
| AppendicitisInfections and infestations | 0/157 | 5/316 |
| GastroenteritisInfections and infestations | 2/157 | 5/316 |
| PneumoniaInfections and infestations | 2/157 | 5/316 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/157 | 5/316 |
| Angina pectorisCardiac disorders | 2/157 | 0/316 |
| Event | Imatinib 400mg | Imatinib 800mg |
|---|---|---|
| NauseaGastrointestinal disorders | 78/157 | 205/316 |
| DiarrhoeaGastrointestinal disorders | 71/157 | 184/316 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 69/157 | 141/316 |
| VomitingGastrointestinal disorders | 54/157 | 140/316 |
| Oedema peripheralGeneral disorders | 43/157 | 135/316 |
| Periorbital oedemaEye disorders | 46/157 | 132/316 |
| FatigueGeneral disorders | 51/157 | 131/316 |
| AnaemiaBlood and lymphatic system disorders | 41/157 | 120/316 |
| RashSkin and subcutaneous tissue disorders | 32/157 | 119/316 |
| ThrombocytopeniaBlood and lymphatic system disorders | 36/157 | 111/316 |
| Age Continuous(years) | Imatinib 400 mg | Imatinib 800 mg | Total |
|---|---|---|---|
| Mean | 46.2 ± 14.90 | 48.2 ± 13.89 | 47.6 ± 14.25 |
| Sex: Female, Male(Participants) | Imatinib 400 mg | Imatinib 800 mg | Total |
|---|---|---|---|
| Female | 73 | 136 | 209 |
| Male | 84 | 183 | 267 |
The record gives a start of Jun 2005, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Leukemia, Myeloid, Chronic-Phase →